Skip to main content
. 2022 Apr 27;198(2):317–327. doi: 10.1111/bjh.18207

FIGURE 1.

FIGURE 1

JAKARTA and JAKARTA2: Enrollment, treatment allocation, and primary reasons for treatment discontinuation for patients with platelet counts of 50 to <100 × 109/l at study entry. aTen patients crossed‐over from placebo to fedratinib after EOC6 and one crossed‐over before EOC6. EOC6, end of cycle 6; HSCT, haematopoietic stem cell transplant